WeVote
Log In

Bill

Bill

LD 104

An Act To Protect The Health Of Medical Cannabis Patients And Streamline The Mandatory Testing Of Cannabis

132nd Legislature (2025-2026) Introduced by Marc Malon

Maine bill to streamline medical cannabis testing requirements while protecting patient health protections; died in committee in May 2025.

Pursuant to Joint Rule 310.3 Placed in Legislative Files (DEAD)
#cannabis #medicalcannabis #testing
0
WeVote Research Nonpartisan
Bill Summary · LD 104

Legislative bill overview

LD 104 proposed to establish health protections for medical cannabis patients in Maine while reforming the state's cannabis product testing requirements. The bill aimed to streamline mandatory testing procedures that producers must follow before products reach patients.

Why is this important

Medical cannabis testing standards directly affect patient safety by ensuring products are free from contaminants like mold, pesticides, and heavy metals. Streamlining these processes could reduce costs for producers—potentially lowering prices for patients—while clarifying regulatory requirements that have created compliance burdens.

Potential points of contention

  • Testing vs. access trade-off: Streamlined testing might accelerate product availability but could raise concerns among patient advocates about whether safety standards remain sufficiently rigorous
  • Industry burden vs. consumer protection: Cannabis producers may support reduced testing mandates to lower operational costs, while regulators and health officials may worry about adequate contamination detection
  • Specificity of reforms: The bill's particular testing modifications are not detailed in available records, making it unclear whether changes represent meaningful improvement or inadequate oversight

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.